Table 5

Antitumor activity of oral BMS-247550 and i.v. paclitaxel

TumorBMS-247550Paclitaxel LCK (GD)2,3
Route, scheduleOD1(mg/kg)Tumor response LCK (GD)2(cures/total)
Pat-7p.o. q2d×560–803.1 (32.8)1.3 (9.8)
p.o. q2d×5802.5 (29.3)1.2 (13.5)
HCT116p.o. q2d×590>6.3 (>69) (7/8 cures)ND4
  • 1 OD, or MTD.

  • 2 GD = delay in tumor growth (days) to target volume (500 or 1000 mm3).

  • 3 LCK are for optimal paclitaxel dose (dose ranged from 24–36 mg/kg, i.v. q2d×5) or highest dose tested, if inactive.

  • 4 ND, not done.